SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
LA JOLLA, Calif., Nov. 15, 2016 -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company developing precision medicines for cancer, today announced it will be presenting two posters at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2016), taking place November 29 – December 2, 2016 in Munich. The presentations will feature preclinical data from Kura Oncology’s KO‒947 ERK inhibitor and menin-MLL inhibitor programs. Abstracts are currently available online at the European Cancer Organisation website (www.ecco-org.eu/Events/ENA2016).
Posters
Date & Time: Nov. 30, 2016, 10:15 a.m. - 5:00 p.m. (CET)
Poster Title: Discovery of novel menin-MLL small molecule inhibitors that display high potency and selectivity in vitro and in vivo
Session: Epigenetic modulators
Abstract Number: 264
Poster Location: P090, ICM – Internationales Congress Center München
Date & Time: Dec. 1, 2016, 10:15 a.m. - 5:00 p.m. (CET)
Poster Title: KO-947, a potent and selective ERK inhibitor with slow dissociation kinetics
Session: Molecular targeted agents II
Abstract Number: 381
Poster Location: P060, ICM – Internationales Congress Center München
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials. The preclinical pipeline includes KO-947, an ERK inhibitor, and a menin-MLL program. For additional information about Kura Oncology, please visit the company’s website at www.kuraoncology.com.
CONTACT INFORMATION INVESTOR CONTACT: Robert H. Uhl Managing Director Westwicke Partners, LLC (858) 356-5932 [email protected] MEDIA CONTACT: Mark Corbae Vice President Canale Communications (619) 849-5375 [email protected]
